Alunbrig (brigatinib) — United Healthcare

Initial criteria

• Diagnosis of anaplastic large cell lymphoma
• Tumor is anaplastic lymphoma kinase (ALK)-positive
• Disease is relapsed OR refractory
• Used as palliative intent therapy OR second-line and subsequent therapy

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Alunbrig therapy

Approval duration

12 months